GLP-1 Drugs Could Extend Life for Colon Cancer Patients, Study Finds

Colon cancer patients taking popular GLP-1 medications like Ozempic and Wegovy may have a significantly better chance of survival, according to promising new research from the University of California San Diego.

The study, published November 11 in the journal Cancer Investigation, examined data from more than 6,800 patients and found that those using GLP-1 drugs had dramatically lower five-year mortality rates compared to non-users. Only 15% of patients taking these medications died within five years, compared to 37% of those not using the drugs.

This survival advantage persisted even after researchers accounted for potential confounding factors such as age, cancer severity, and other health conditions, suggesting the medications may offer genuine benefits beyond their established use for diabetes management and weight loss.

“The central message is that GLP-1 medications were associated with substantially lower five-year mortality among patients with colon cancer, and that this signal was most pronounced in those with severe obesity, with BMI at or above 35,” explained lead study author Raphael Cuomo, associate professor in UC San Diego’s Department of Anesthesiology and member of the university’s Moores Cancer Center.

The findings point to a possible connection between metabolic health and cancer outcomes. GLP-1 medications are known to reduce inflammation, lower insulin levels, and promote weight loss – all factors that could potentially slow cancer progression. Some researchers theorize these drugs might even act directly on tumor cells, though this mechanism remains unproven.

Dr. Sue Decotiis, a medical weight loss specialist in New York City who wasn’t involved in the study, noted that GLP-1 drugs significantly reduce systemic inflammation by decreasing inflammatory factors called cytokines that are produced by fat cells.

“It could be a direct effect of the GLP-1 drug to reduce inflammation in particular areas, and therefore it is not surprising to see better cancer survival,” Decotiis said.

The research comes amid growing interest in the broader health impacts of GLP-1 medications beyond their approved uses. Originally developed for diabetes management, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have gained widespread attention for their effectiveness in treating obesity, which affects more than 40% of American adults and is a known risk factor for colon cancer.

Despite the encouraging results, the researchers emphasized important limitations in their study. As an observational analysis, it established an association between GLP-1 use and improved survival but couldn’t prove causation. The researchers also acknowledged that the number of patients receiving GLP-1 medications was relatively modest compared to the overall study group, and they lacked complete information on dosage, duration, and adherence for every individual.

“Patients should not interpret these findings as evidence that GLP-1 medications are proven cancer drugs,” Cuomo cautioned. “For now, the appropriate way to act on this work is to ensure that people with colon cancer who also have obesity or diabetes are offered guideline-supported metabolic therapies, including GLP-1 agents when clinically indicated, as part of comprehensive care.”

Medical experts stress that further research, particularly randomized controlled trials, will be necessary to definitively establish whether these medications can improve cancer outcomes. However, the study provides a “hopeful signal” that treating metabolic conditions alongside cancer could yield better results.

“It suggests that we may be able to improve cancer outcomes by treating the whole person and not just the tumor, and that modern metabolic therapies could have unanticipated benefits for patients with malignancy,” Cuomo added.

The findings underscore the interconnected nature of health conditions and highlight the potential importance of maintaining healthy weight and optimal metabolic function for cancer patients. As research continues, GLP-1 medications may eventually play a more formal role in comprehensive cancer care strategies, particularly for patients who also struggle with obesity or diabetes.

For now, researchers view these results as a promising direction for future investigation rather than a definitive treatment recommendation.